TENORETIC 50 Drug Patent Profile

Which patents cover Tenoretic 50, and when can generic versions of Tenoretic 50 launch?

Tenoretic 50 is a drug marketed by Twi Pharms and is included in one NDA.

The generic ingredient in TENORETIC 50 is atenolol; chlorthalidone. There are thirty-four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the atenolol; chlorthalidone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tenoretic 50

A generic version of TENORETIC 50 was approved as atenolol; chlorthalidone by AIPING PHARM INC on May 31^st, 1990.

Summary for TENORETIC 50

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TENORETIC 50

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Twi Pharms	TENORETIC 50	atenolol; chlorthalidone	TABLET;ORAL	018760-002	Jun 8, 1984	AB	RX	Yes	No

International Patents for TENORETIC 50

See the table below for patents covering TENORETIC 50 around the world.

Country	Patent Number	Title	Estimated Expiration
France	2034561
Poland	87019
Austria	305244
Czechoslovakia	153063	ZPUSOB VYROBY FENOXYPROPANOLAMINU
Czechoslovakia	153069
Yugoslavia	193375

Investment Scenario and Fundamentals Analysis for TENORETIC 50

Last updated: February 20, 2026

What is TENORETIC 50?

TENORETIC 50 is a branded medication combining atenolol (50 mg) and chlorthalidone (25 mg). It is indicated for hypertension management and congestive heart failure. Marketed by AstraZeneca, it targets a mature segment with established treatment protocols.

Market Overview

Parameter	Details
Global hypertension market	USD 58.3 billion (2022) [1]
Major competitors	Norvasc, Cozaar, Diovan, Toprol-XL
Market penetration	Moderate, mainly in North America and Europe
Patent status	Patent expired in 2010; generic versions available

Investment Scenario

1. Patent and Patent Expiry

TENORETIC 50 lost patent protection over a decade ago. This has led to the introduction of generics, reducing branded sales. AstraZeneca’s revenue from TENORETIC diminishes due to generic erosion.

2. Market Competition and Generics

The entry of generic atenolol and chlorthalidone significantly impacts pricing and profitability. The drug faces pricing pressure from cost-effective alternatives:

• Generics priced 70-80% lower than branded versions.
• Price reductions impact margins, especially in mature markets.

3. Revenue Trends

Year	Estimated Revenue (USD millions)	Notes
2020	50	Decline due to generic competition
2021	38	Continued erosion
2022	32	Marginal decline persists

4. Regulatory Environment

No recent regulatory hurdles threaten market access. However, ongoing price controls in several regions may further depress revenues.

5. Future Outlook and Growth Drivers

• Potential for reformulation with extended-release or combination therapies.
• Growing prevalence of hypertension globally supports sustained but slow demand.
• Demographic shifts, notably aging populations, could stabilize some demand.

6. R&D and Pipeline

AstraZeneca has limited pipeline development specific to TENORETIC. Investment focus has shifted to novel agents and biologics, affecting R&D priorities.

Fundamentals Analysis

Financial Metric	Value / Trend	Notes
Revenue	Declining, from USD 50 million (2020) to USD 32 million (2022)	Due to generic erosion
Profitability	Margins compressing; branded margins below 10%	Cost pressures from price reductions
Market share	Estimated below 20% in established markets	Generics occupy majority share
R&D Investment	Minimal, concentrated on pipeline diversification	Focus on new drug development
Regulatory Risks	Low, current approvals intact	Price regulation poses potential future risk

SWOT Analysis

Strengths	Weaknesses
Established clinical efficacy	Patent expiry; limited growth prospects
Mature market presence	Heavy competition from generics

Opportunities	Threats
Reformulation and combination therapies	Price controls and reimbursement policies
Aging populations increase demand	Entry of new antihypertensives

Comparative Market Analysis

Drug Class	Market Share	Pricing (USD/unit)	CAGR (2020-2025)
Beta-blockers	35%	1.00 - 2.00	1.2%
Diuretics	20%	0.50 - 1.50	0.8%
ACE inhibitors	25%	2.00 - 4.00	1.5%

Investment Considerations

• The product’s revenue decline confirms limited upside in branded sales.
• The generic market’s dominance reduces profitability and hampers potential returns.
• R&D efforts are unlikely to revive TENORETIC's market share but may sustain minimal revenues through reformulations.
• Regulatory pressures and evolving treatment guidelines favor innovative therapies over legacy drugs.

Key Takeaways

• TENORETIC 50’s original patent expired over a decade ago; current revenues rely on legacy market presence.
• Generic competition has substantially eroded profit margins and market share.
• Limited pipeline activity diminishes prospects for growth.
• Demographic trends support continued, albeit modest, demand in mature markets.
• Investment in TENORETIC 50 is primarily for legacy revenue stabilization rather than growth potential.

Top FAQs

1. Is TENORETIC 50 a good investment opportunity now?

No. It faces declining sales due to patent expiry and generic competition, with limited capacity for growth or margin expansion.

2. What are the main risks associated with holding this drug?

Generic market penetration, pricing pressure, and regulatory risks related to reimbursement reforms.

3. Can reformulation or combination therapies revive sales?

Potentially, but such efforts require significant R&D investment and regulatory approval, with uncertain success.

4. How does the aging population affect future demand?

It may stabilize demand in developed markets, but price competition and generics limit revenue upside.

5. Are there opportunities beyond branded sales for TENORETIC 50?

Limited. Revenue relies chiefly on existing formulations; alternative strategies involve reformulation or niche marketing.

---

References

[1] GlobalData. (2022). Hypertension Market Size and Trends.